Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics

Shaji Kumar, Rafael Fonseca, Rhett P. Ketterling, Angela Dispenzieri, Martha Q. Lacy, Morie A. Gertz, Suzanne R. Hayman, Francis K. Buadi, David Dingli, Ryan A. Knudson, Alexandra Greenberg, Stephen J. Russell, Steven R. Zeldenrust, John A. Lust, Robert A. Kyle, Leif Bergsagel, S. Vincent Rajkumar

Research output: Contribution to journalArticle

147 Scopus citations

Abstract

Routine incorporation of FISH into multiple myeloma (MM) diagnostic testing has led to a better appreciation of the heterogeneity of genetic abnormalities associated with this disease. We studied a group of 484 patients with newly diagnosed symptomatic MM to better understand the prevalence of the various abnormalities and the prognostic significance of the overlapping abnormalities. A translocation involving the IgH locus and 1 of the 5 recurrent partner chromosomes was seen in 161 (33%) patients, and 275 (57%) had trisomy of at least 1 odd-numbered chromosome. High-risk FISH, defined as the presence of t(4;14), t(14;16), t(14;20), or loss of P53, was seen in 115 (24%) patients; the median overall survival for this group was 3.9 years, compared with "not reached" for standard-risk patients (P < .001). Among the patients with highrisk FISH, 49 patients who also had at least 1 trisomy had a median overall survival that was not reached, compared with 3 years for high-risk patients without a concurrent trisomy (P = .01). Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities inMMameliorates the usual adverse impact associated with these prognostic markers.

Original languageEnglish (US)
Pages (from-to)2100-2105
Number of pages6
JournalBlood
Volume119
Issue number9
DOIs
StatePublished - Mar 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this